Amgen Inc
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen GAAP Total Operating Expenses by Quarter
GAAP Total Operating Expenses ($M) ($M)
Amgen GAAP Total Operating Expenses: $6,540M in Q2 2026, up 0.3% from a year earlier.
Latest, Q2 2026
6,540
Period ended Jun 30, 2026
Change on a year earlier
+0.3%
6,523 in Q2 2025
History
36 quarters
Since Q3 2017
Sources
32
Documents cited below
Where the Q2 2026 figure comes from
“|| Total Operating Expenses | $ | 6,540 | $ | 6,523 | 0% | $ | 5,442 | $ | 4,886 | 11%”
Source: Form 8-K (amgn-20260630earningsrelea.htm, filed 2026-08-04) ↗
Reported in Form 8-K Reconciliations of GAAP to Non-GAAP Measures.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Amgen GAAP Total Operating Expenses ($M), quarterly Q3 2017–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/gaap-opex-8k
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.